MYMD VS SNTI Stock Comparison
Performance
MYMD10/100
10/100
MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.
SNTI10/100
10/100
SNTI returned -84.82% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
MYMD25/100
25/100
MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
SNTI18/100
18/100
SNTI receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.
Profit
MYMD10/100
10/100
Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.
SNTI12/100
12/100
Out of the last 11 quarters, SNTI has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
MYMD40/100
40/100
MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.
SNTI19/100
19/100
SNTI has had a lower than average amount of volatility over the last 12 months giving it a score of 19 of 100.
Earnings
MYMD
"Earnings" not found for MYMD
SNTI100/100
100/100
SNTI has missed earnings 0 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary
Nasdaq / MYMD
Healthcare
Biotechnology
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Senti Biosciences, Inc. Common Stock Summary
Nasdaq / SNTI
Healthcare
Biotechnology
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare MYMD to other companies in the same or a similar industry.